Drug intelligence / Profile preview

ENA-003

Development stage: Unknown
Lead developer: Enalare Therapeutics
Modality: Small Molecules

Overview

ENA-003 is a small molecule opioid receptor antagonist being developed by Enalare Therapeutics for the treatment of drug overdose-induced respiratory depression. The drug is designed to reverse or prevent the life-threatening suppression of breathing caused by opioids. Currently in Phase 2 clinical development, ENA-003 represents a potential therapeutic option for emergency intervention in opioid overdose scenarios, aiming to restore normal ventilatory function by blocking the effects of opioids at their receptor sites.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ENA-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENA-003.

Explore the full profile